



Figure S1


A



B



C



D





Figure S2

A



B






Figure S3


A



B



C



D






Figure S4


A




B



C



D



E




Fig S5







Untreated

C5a-treated

STING agonist


C5aR1 KO

C5aR2 KO




GSEA of wildtype versus C5aR1 (left) or C5aR2 (right) cells, left untreated or treated with C5a or STING agonist.

### Figure S6



### Figure S7





### Figure S8

